Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Covalon Technologies Ltd V.COV

Alternate Symbol(s):  CVALF

Covalon Technologies Ltd. is a patient-driven medical device company. Through a portfolio of patented technologies and solutions for advanced wound care, infection prevention, and medical device coatings, the Company offers gentler and more compassionate options for patients to heal with less infections, less pain, and better outcomes. Its solutions are designed for patients and made for care providers. It leverages its patented medical technology platforms and expertise in two ways: by developing products that are sold under Covalon’s name and by developing and commercializing medical products for other medical companies under development and license contracts. It provides a range of specialized medical devices, medical dressings and advanced medical technology designed for infection prevention, complex wound closure and perioperative care. Its perioperative care solutions provide antimicrobial protection of pre-operative skin, through postoperative incision care to scar prophylaxis.


TSXV:COV - Post by User

Bullboard Posts
Comment by zenvestingon Oct 20, 2014 11:43am
72 Views
Post# 23043438

RE:10 million warrants?

RE:10 million warrants?Read the financial statetments.  On page 24 of their Inerim financial statement dated August 27, 2014 they show the following "potentially dilutive securities outstanding":  

- under stock options:                                       850,998
- under warrants:                                            5,793,250
-  under terms of convertible debenture:    4,838,710    
TOTAL POTENTIAL DILUTION (TPD):     11,482,958

The warrants consist of 955,000 exercisable @ $1.00 until 10/26/2017 & 4,838,250 @ $0.155 until 8/31/2016.  

The options have an average exercise price of $1.33

Basic shares =    9,276,171
TPD =                 11,482,958

Total Potential OS:  20,759,129

My personal opinion is that this is a pretty tight corporate structure with the Chairman and CEO holding about half of the total potential OS.  While I wasn't exactly impressed with management completing the convertible debenture financing at the bottom of the market in the summer of 2013, the turn to profitability and cash from Molnlycke should provide some assurance that no further dillution will be needed in the near term and will hopefully give the company enough time to implement their business plan to sign more major licensing agreements with market leading companies that can build substantial royalty streams for the company's intelllectual properties.      



Bullboard Posts